Industry News

Atea Pharmaceuticals Announces Strategic Collaboration with Roche to Develop and Distribute AT-527 for Patients with COVID-19 Roche Obtains Exclusive Right to Develop and Distribute AT-527 Outside the United States


Excerpt from the Press Release: BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announces that the company has entered into an agreement with Roche (SIX: RO, ROG; OTCQX:…

Read More

Fabric Genomics Launches GEM Algorithm to Accelerate Genetic Disease Diagnosis, Provide Comprehensive Clinical-Decision Support


Excerpt from the Press Release: OAKLAND, Calif.–(BUSINESS WIRE)–Fabric Genomics, a global leader in clinical interpretation of genomic data, announced today the launch of Fabric GEM, a novel algorithm that quickly and efficiently identifies the likely genetic cause of rare diseases from next-generation sequencing data – enabling faster diagnosis and the possibility of faster and more…

Read More

Moderna enrolls final volunteers into key coronavirus vaccine study


Excerpt from the Article: When Moderna began research on a vaccine for the virus now known as SARS-CoV-2 in late January, confirmed cases of infection were largely contained within China and the public health catastrophe that’s since unfolded was a threat, not reality.  The prospect of designing, testing, and proving a vaccine within a year…

Read More

Listen: How the FDA thinks about Covid-19 vaccines, biotech’s SPAC fascination, & Biogen’s case in Alzheimer’s


Check out the latest from The Readout Loud podcast: “Whose voice rings loudest at the FDA? Is it wise to give hedge funds a blank check? And how will the Biogen saga end? We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Helen Branswell joins us to…

Read More

Gene Therapy Company AavantiBio Launches with $107 Million Series A Financing from Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management and Sarepta Therapeutics


Excerpt from the Press Release: CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) — A premier syndicate of life sciences investors including Perceptive Advisors, Bain Capital Life Sciences (“Bain Capital”), and RA Capital Management (“RA Capital”) (collectively the “Investor Group”) together with Sarepta Therapeutics, Inc. (“Sarepta”) (NASDAQ: SRPT), a leader in precision genetic medicine for rare…

Read More

Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Therapeutics’ Large Phase 2 Clinical Trial of Abivertinib in Mild, Moderate and Severe COVID-19 Patients


Excerpt from the Press Release: SAN DIEGO, Oct. 14, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a Phase 2 clinical trial of Abivertinib in mild, moderate and severe COVID-19 patients. The Brazil study is a Phase 2, Randomized,…

Read More

Lactiga Announces NIH-Funded Partnership with Mount Sinai to Advance its Patented Biologic for COVID-19 Treatmen


Excerpt from the Press Release: PRINCETON, N.J.–(BUSINESS WIRE)–Lactiga Inc., a biotechnology company advancing its patented anti-infective biologic, LCTG-001, announced today a collaboration agreement with the Icahn School of Medicine at Mount Sinai to advance preclinical research into LCTG-001 as a potential treatment for COVID-19 patients. The collaborative team, led by Dr. Rebecca Powell, Assistant Professor…

Read More

National Institutes of Health Launches its ACTIV-5 “Big Effect Trial” Evaluating Humanigen’s Lenzilumab™ as Potential COVID-19 Therapy


Excerpt from the Press Release: Burlingame, CA – October 13, 2020 – Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate lenzilumab™, today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S.…

Read More

Moderna Announces Initiation of Rolling Submission to Health Canada for mRNA Vaccine Against COVID-19 (mRNA-1273)


Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the initiation of a rolling submission to Health Canada for mRNA-1273, the Company’s vaccine candidate against COVID-19. This initiation follows positive results…

Read More

Journal of Affective Disorders Publishes Clinical Data Suggesting NeuroStar® Advanced Therapy as a First-line Treatment for Major Depressive Disorder


Excerpt from the Press Release: MALVERN, Pa., Oct. 13, 2020 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today that clinical data from its NeuroStar Outcomes Registry, which suggests…

Read More